Barclays raised the firm’s price target on Cigna to $405 from $393 and keeps an Overweight rating on the shares post the Q2 report. The firm does not see a material shift in Cigna’s 2024 cost trend outlook and believes the stock reaction was overdone.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CI: